Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure
- 1 January 2015
- journal article
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- The war against heart failure: the Lancet lectureThe Lancet, 2015
- Prognostic Value of Soluble ST2 in the Valsartan Heart Failure TrialCirculation: Heart Failure, 2014
- Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fractionInternational Journal of Cardiology, 2014
- Head-to-Head Comparison of Serial Soluble ST2, Growth Differentiation Factor-15, and Highly-Sensitive Troponin T Measurements in Patients With Chronic Heart FailureJACC: Heart Failure, 2014
- Biomarkers in Cardiology - Part 1 - In Heart Failure and Specific CardiomyopathiesArquivos Brasileiros de Cardiologia, 2014
- Head-to-Head Comparison of 2 Myocardial Fibrosis Biomarkers for Long-Term Heart Failure Risk StratificationJournal of the American College of Cardiology, 2014
- Heart Failure Therapy–Induced Early ST2 Changes May Offer Long-Term Therapy GuidanceJournal of Cardiac Failure, 2013
- Soluble Concentrations of the Interleukin Receptor Family Member ST2 and β-Blocker Therapy in Chronic Heart FailureCirculation: Heart Failure, 2013
- Soluble ST2 Serum Concentration and Renal Function in Heart FailureJournal of Cardiac Failure, 2013
- Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapyCritical Care, 2012